218 patents
Page 6 of 11
Utility
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
25 Jan 22
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
Filed: 16 Sep 20
Utility
Tertiary alcohols as PI3K-γ inhibitors
18 Jan 22
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
Filed: 26 Jun 20
Utility
Topical formulation for a JAK inhibitor
11 Jan 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 17 Sep 20
Utility
Pyrrole tricyclic compounds as A2A / A2B inhibitors
11 Jan 22
Xiaozhao Wang, Peter Niels Carlsen, Chunhong He, Taisheng Huang
Filed: 8 Apr 19
Utility
Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
4 Jan 22
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 2 Mar 20
Utility
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
4 Jan 22
The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Wenqing Yao, David M. Burns, Jincong Zhuo
Filed: 13 Nov 19
Utility
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
28 Dec 21
The present invention is directed to 1, 2, 5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2, 3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1, 2, 5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
Filed: 15 Apr 20
Utility
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
7 Dec 21
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
Andrew P. Combs, Eddy W. Yue
Filed: 10 Jan 19
Utility
Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
30 Nov 21
The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.
Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
Filed: 4 Sep 19
Utility
Bicyclic heterocycles as FGFR4 inhibitors
16 Nov 21
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 12 Mar 20
Utility
Salts of an FGFR inhibitor
16 Nov 21
The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.
Zhongjiang Jia, Jiacheng Zhou, Qun Li
Filed: 3 May 19
Utility
Fused pyrimidine derivatives as A2A / A2B inhibitors
9 Nov 21
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
Filed: 17 May 19
Utility
Heterocyclic derivatives as PI3K inhibitors
2 Nov 21
Stacey Shepard, Yanran Ai, Andrew P. Combs, Artem Shvartsbart
Filed: 12 Nov 19
Utility
Fused pyrazine derivatives as A2A / A2B inhibitors
2 Nov 21
Xiaozhao Wang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu
Filed: 3 Jul 19
Utility
Tricyclic fused thiophene derivatives as JAK inhibitors
2 Nov 21
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
Filed: 27 Jun 19
Utility
Cyclopropylamines as LSD1 inhibitors
26 Oct 21
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Wenqing Yao
Filed: 1 May 20
Utility
Pyrrolopyrimidine derivatives as TAM inhibitors
5 Oct 21
Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
Filed: 15 Nov 19
Utility
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
28 Sep 21
Yun-Long Li, Andrew P. Combs
Filed: 8 Oct 19
Utility
Heterocyclic compounds as immunomodulators
21 Sep 21
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 23 Apr 20
Utility
Pyrazolopyrimidine compounds and uses thereof
7 Sep 21
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
Filed: 24 Sep 19